Prognostic Factors for Survival in Advanced Oesophageal Cancer
Author Information
Author(s): Polee M B, Hop W C J, Kok T C, Eskens F A L M, van der Burg M E L, Splinter T A W, Siersema P D, Tilanus H W, Stoter G, van der Gaast A
Primary Institution: Erasmus Medical Center, Rotterdam, The Netherlands
Hypothesis
What factors predict survival in patients with advanced oesophageal cancer treated with cisplatin-based chemotherapy?
Conclusion
Performance status, extent of disease, and lactate dehydrogenase levels are key factors influencing survival in patients with advanced oesophageal cancer receiving chemotherapy.
Supporting Evidence
- Patients with a performance status of 0 had a median survival of 12 months.
- Patients with extensive disease had a median survival of only 7 months.
- Elevated lactate dehydrogenase levels were associated with poorer survival outcomes.
Takeaway
Doctors can better predict how long patients with advanced oesophageal cancer might live by looking at their health status and how far the cancer has spread.
Methodology
The study analyzed data from six prospective clinical trials involving patients treated with cisplatin-based chemotherapy.
Potential Biases
Potential bias due to the non-randomized nature of the studies analyzed.
Limitations
The study lacks randomized phase III trials comparing chemotherapy to supportive care alone.
Participant Demographics
The study included 350 patients, predominantly male (79%), with a median age of 56 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 8–10 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website